Chairing the ACR’s Communications and Marketing Committee (CMC) can be a monumental task: The CMC is responsible for both internal and external communications to a variety of people, including rheumatology providers, patients, lawmakers, the pharmaceutical industry and others. But the CMC’s newest chair, Suleman Bhana, MD, FACR, is up for the job. The Rheumatologist recently…
Rheumatologists may benefit from the decentralized technology that makes cryptocurrency possible: blockchain. According to Anh L. Ngo, MD, MBA, using blockchain in healthcare may increase payment and purchasing efficiency and revolutionize EHR management…
The FDA has approved halobetasol propionate lotion as a topical treatment for plaque psoriasis…
The FDA has approved an update for rituximab’s label, which will include safety and efficacy information for treating ANCA-associated vasculitis…
In a four-year study, patients with active psoriatic arthritis (PsA) experienced sustained improvement in PsA signs and symptoms on secukinumab…
A study published in the May issue of Arthritis Care & Research may be the first to examine the long-term outcomes of childhood-onset lupus, otherwise known as pediatric systemic lupus erythematosus (SLE), a chronic, multisystem autoimmune disease with a highly variable clinical course. Previous studies examined cross-sectional views of damage accrued. According to the Childhood…
Indigenous communities in Latin America lack good healthcare—and often lack any healthcare—for musculoskeletal and rheumatic diseases.1 Global health initiatives tend to focus on infectious disease, despite the increasing rate of chronic diseases. In a survey of 6,155 individuals from eight indigenous communities, conducted by a team of Latin American investigators, the prevalence of these conditions…
Recent data showing sustained, long-term safety and efficacy of mavrilimumab for the treatment of rheumatoid arthritis (RA) confirm and build on prior evidence from phase 2 studies of the potential for this new agent for the treatment of RA. Mavrilimumab is a human monoclonal antibody that blocks a proinflammatory cytokine involved in RA pathogenesis—granulocyte-macrophage colony-stimulating…
CHICAGO—At the 2018 ACR/ARHP Annual Meeting in October, the ACR and the ARHP honored distinguished individuals who have made significant contributions to rheumatology research, education and patient care. This month, The Rheumatologist speaks with the ACR winners about their individual contributions to advancing rheumatology. You’ll also find the 2018 Masters list. In the next issue,…
Missed appointments have long been a problem for rheumatology practices. A recent poll from the Medical Group Management Association (MGMA) found no-shows were the single biggest challenge reported by practice leaders, with 44% of respondents citing the issue.1 If a patient does not come to the office when scheduled, it starts a cascade of events…